InMode (INMD) Stock Price, News & Analysis

Company Overview

InMode Ltd. is an Israel-based medical technology company that develops, manufactures and markets energy-based platforms for aesthetic and medical treatments. Its technologies are designed to support minimally invasive and noninvasive procedures in areas such as skin rejuvenation, facial and body contouring, hair removal, intimate health and other soft-tissue applications.

The company’s product portfolio includes radiofrequency and other energy-based systems sold under brands such as Morpheus8, BodyTite, FaceTite, Forma and Lumecca. These platforms are used by physicians and other medical professionals in dermatology, plastic surgery and aesthetic practices, with applications that may include tissue remodeling, skin tightening, fat reduction and treatment of skin conditions.

InMode sells its products internationally through a combination of direct sales and distributors, serving customers in North America, Europe, Asia-Pacific, Latin America and other markets. The company was founded in 2008 and is headquartered in Yokneam, Israel. InMode became a publicly traded company on the Nasdaq in 2019 and has been led by co-founder Moshe Mizrahy, who serves as chief executive officer.

Key Stats

• Today's Range: $14.32 to $14.50
• 50-Day Range: $13.99 to $15.37
• 52-Week Range: $12.72 to $16.67
• Volume: 222,674 shs
• Average Volume: 807,986 shs
• Market Capitalization: $826.40 million
• P/E Ratio: 11.69
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Hold

InMode Stock Analysis - MarketRank™

InMode scored higher than 34% of companies evaluated by MarketBeat, and ranked 725th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

InMode has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.

Upside Potential

InMode has a consensus price target of $16.00, representing about 11.4% upside from its current price of $14.36.

Amount of Analyst Coverage

InMode has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of InMode is 11.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of InMode is 11.67, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.58.

Price to Book Value per Share Ratio

InMode has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.21% of the float of InMode has been sold short.

Short Interest Ratio / Days to Cover

InMode has a short interest ratio ("days to cover") of 5.03.

Change versus previous month

Short interest in InMode has recently decreased by 4.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InMode does not currently pay a dividend.

Dividend Growth

InMode does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.57

News Sentiment

InMode has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for InMode this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added InMode to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InMode insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.92% of the stock of InMode is held by insiders.

Percentage Held by Institutions

68.04% of the stock of InMode is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:INMD
• CIK: 1742692
• Web: www.inmodemd.com
• Phone: 972-4909-7470
• Fax: N/A
• Employees: 660
• Year Founded: 2008

Price Target and Rating

• Average Price Target for InMode: $16.00
• High Price Target: $19.00
• Low Price Target: $14.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.23
• Trailing P/E Ratio: 11.69
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $93.83 million
• Net Margins: 20.69%
• Pretax Margin: 24.28%
• Return on Equity: 11.99%
• Return on Assets: 10.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.18
• Quick Ratio: 7.28

Sales & Book Value

• Annual Sales: $374.63 million
• Price / Sales: 2.21
• Cash Flow: $1.51 per share
• Price / Cash Flow: 9.52
• Book Value: $10.78 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 57,481,000
• Free Float: 53,503,000
• Market Cap: $826.29 million
• Optionable: Optionable
• Beta: 2.03